A PHASE 1, MULTICENTER, OPEN-LABEL, DOSEESCALATING SAFETY STUDY OF HUMAN CORD BLOOD DERIVED, CULTURE EXPANDED NATURAL KILLER CELL (PNK-007) INFUSION WITH SUBCUTANEOUS RECOMBINANT HUMAN IL-2 (RHIL-2) IN ADULTS WITH RELAPSED AND/OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CCT-PNK-007-AML-001

To Learn More Call
201-510-0910